DCs possess the capability to capture antigens generated and released during tumorigenesis, subsequently presenting tumor antigens to naive CD8+ T and CD4+ T cells through major histocompatibility complex (MHC)-I and MHC-II molecules. This evidence concerns the gene CD4 and neoplasm.